Over the past two decades, research organizations and pharmaceutical companies have invested billions of dollars into the development of new biopharmaceutical medicines. This research has resulted in a burgeoning biopharmaceutical industry, with ground-breaking advances in treatments for severe systemic illnesses such as cancer and hemophilia. However, the focus of academic research has historically been centered on drug discovery and development rather than on operational issues relating to drug manufacture. In the past five to ten years there has been an…